INTERCEPT PHARMACEUTICALS INC·4

Jan 9, 9:30 PM ET

INTERCEPT PHARMACEUTICALS INC 4

4 · INTERCEPT PHARMACEUTICALS INC · Filed Jan 9, 2014

Insider Transaction Report

Form 4
Period: 2014-01-07
Transactions
  • Sale

    Common Stock

    2014-01-07$67.41/sh1,839$123,9671,640 total
Holdings
  • Common Stock

    (indirect: See Footnote)
    5,938,890
Footnotes (2)
  • [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 18, 2013.
  • [F2]Held by Genextra S.p.A. Dr. Tallarigo is the chief executive officer of Genextra S.p.A. and, in such capacity, Dr. Tallarigo exercises voting control over the shares of common stock owned by Genextra S.p.A. and investment control over such shares as authorized by the board of directors of Genextra S.p.A. Dr. Tallarigo disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.

Documents

1 file
  • 4
    v365085_4.xmlPrimary

    OWNERSHIP DOCUMENT